0001193125-17-248863.txt : 20170906 0001193125-17-248863.hdr.sgml : 20170906 20170804171503 ACCESSION NUMBER: 0001193125-17-248863 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RXi Pharmaceuticals Corp CENTRAL INDEX KEY: 0001533040 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 257 SIMARANO DRIVE STREET 2: SUITE 101 CITY: MARLBOROUGH STATE: MA ZIP: 01752 BUSINESS PHONE: (508) 767-3861 MAIL ADDRESS: STREET 1: 257 SIMARANO DRIVE STREET 2: SUITE 101 CITY: MARLBOROUGH STATE: MA ZIP: 01752 CORRESP 1 filename1.htm CORRESP

RXi Pharmaceuticals Corporation

257 Simarano Drive, Suite 101 | Marlborough, MA 01752

August 4, 2017

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Attn: Christine Westbrook

 

  Re: RXi Pharmaceuticals Corporation
       Registration Statement on Form S-1 (File No. 333-219300)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, RXi Pharmaceuticals Corporation (the “Company”) hereby requests that the effective date of the above-captioned registration statement (the “Registration Statement”) be accelerated so that it becomes effective at 4:00 p.m., Eastern Time, on August 8, 2017, or as soon thereafter as practicable.

Please call Ryan Murr of Gibson, Dunn & Crutcher LLP at (415) 393-8373 as soon as the Registration Statement has been declared effective.

 

Very truly yours,

 

RXi PHARMACEUTICALS CORPORATION

By:   /s/ Geert Cauwenbergh
 

Name: Geert Cauwenbergh, Dr. Med. Sc.

Title: President, Chief Executive Officer and Chief Financial Officer